Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1995 5
1996 1
1997 1
1998 6
1999 2
2000 7
2001 1
2002 1
2005 1
2007 1
2010 1
2011 2
2015 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Results by year
Filters applied: . Clear all
Page 1
PPAR alpha and the regulation of cell division and apoptosis.
Roberts RA, Chevalier S, Hasmall SC, James NH, Cosulich SC, Macdonald N. Roberts RA, et al. Among authors: james nh. Toxicology. 2002 Dec 27;181-182:167-70. doi: 10.1016/s0300-483x(02)00275-5. Toxicology. 2002. PMID: 12505304 Review.
Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.
Nakamura K, Karmokar A, Farrington PM, James NH, Ramos-Montoya A, Bickerton SJ, Hughes GD, Illidge TM, Cadogan EB, Davies BR, Dovedi SJ, Valge-Archer V. Nakamura K, et al. Among authors: james nh. Clin Cancer Res. 2021 May 19. doi: 10.1158/1078-0432.CCR-20-3701. Online ahead of print. Clin Cancer Res. 2021. PMID: 34011558 Free article.
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
Brave SR, Odedra R, James NH, Smith NR, Marshall GB, Acheson KL, Baker D, Howard Z, Jackson L, Ratcliffe K, Wainwright A, Lovick SC, Hickinson DM, Wilkinson RW, Barry ST, Speake G, Ryan AJ. Brave SR, et al. Among authors: james nh. Int J Oncol. 2011 Jul;39(1):271-8. doi: 10.3892/ijo.2011.1022. Epub 2011 Apr 29. Int J Oncol. 2011. PMID: 21537841
Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.
Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, Jürgensmeier JM, Womack C. Smith NR, et al. Among authors: james nh. Clin Cancer Res. 2010 Jul 15;16(14):3548-61. doi: 10.1158/1078-0432.CCR-09-2797. Epub 2010 Jul 6. Clin Cancer Res. 2010. PMID: 20606037 Free article.
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ. Wedge SR, et al. Among authors: james nh. Cancer Res. 2005 May 15;65(10):4389-400. doi: 10.1158/0008-5472.CAN-04-4409. Cancer Res. 2005. PMID: 15899831 Free article.
Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST. Brave SR, et al. Among authors: james nh. Mol Cancer Ther. 2011 May;10(5):861-73. doi: 10.1158/1535-7163.MCT-10-0976. Epub 2011 Mar 25. Mol Cancer Ther. 2011. PMID: 21441409 Free article.
33 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page